Gallstones
Logo

Koli Inc

The non-surgical treatment for gallstone disease.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Fremont, CA, USA
  • Currency USD
  • Founded December 2012
  • Employees 4
  • Incorporation Type C-corp
  • Website kolimedical.com

Company Summary

Kōli has developed a catheter-based solution for gallstone disease. Symptomatic gallstone disease affects more than 25 million people and consumes more than $20B globally. Surgical removal of the gallbladder is currently the only definitive treatment. Kōli offers a safer, non-surgical alternative which does not require general anesthesia or removal of the gallbladder. The device is currently undergoing clinical trials in Europe.

Team

  • Default avatar
    Christopher Cheng
    CEO

    Chris has 20 years of experience in biomedical research and medical device development and is a Consulting Professor of Surgery at Stanford University. Chris graduated from Duke and Stanford, and was previously an Entrepreneur In Residence at NDC, General Manager of Tendyne Medical, Director of Technology of NovoStent, and Principal Engineer at J&J.

  • Default avatar
    Matthew Callaghan
    CMO

    Matt is an alumnus of Stanford’s Biodesign Program and a Consulting Assistant Professor of Surgery at Stanford University. He graduated from Carnegie-Mellon and has an MD from the State University of NY. Matt trained in general surgery at UCSF and is the founder of three medical device companies including Kōli. Matt is a practicing physician at the San Francisco VA Medical Center.

  • 2069b241 7843 49d8 8edf c985844e6866
    Senior R+D Manager

    Vrad has 15 years of experience in biomedical research and catheter-based medical device development. He graduated from U. Texas and Duke, and brought 7 devices to market as a medical device engineer at W.L. Gore & Associates.

  • 7d0a374e 69ed 4bfb 8d96 3e8b2bfa2431
    Senior R+D Manager

    Steven has over 20 years of experience in the medical device industry, with experience ranging from early R&D exploration to commercialization. He has worked for Haemonetics, Cordis, Intella Interventional, Abbott Labs, iScience Interventional, and Transcend Medical.

Advisors

  • Default avatar
    Chris Shen
    Unconfirmed
    Default avatar
    Daniel Sze
    Unconfirmed

Previous Investors

  • Default avatar
    National Science Foundation
    Unconfirmed